Colorectal Cancer

Elena Garralda, ASCO 2021: Favezelimab in Metastatic Colorectal Cancer

touchONCOLOGY joins Dr Elena Garralda (Vall d’Hebron Institute of Oncology, Barcelona, Spain) at ASCO 2021 to discuss favezelimab in metastatic colorectal cancer. The abstract ‘A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer (NCT02720068)’ (abstract number 3584) was presented at the 2021 ASCO […]

Hans Prenen, ASCO GI 2021: Updates from the alloSHRINK Study

It was a pleasure to talk to Hans Prenen about recent updates in CAR T cell therapy and the current findings from the alloSHRINK study (Clinical Trial Identifier: NCT03692429). The abstract ‘Updated data from alloSHRINK phase I first-in-human study evaluating CYAD-101, an innovative non-gene edited allogeneic CAR-T in mCRC.’ (ABSTRACT NUMBER: 74) was presented at […]

Precision Medicine in Metastatic Colorectal Cancer—Finding and Hitting the Right Targets

Oncology & Hematology (US). 2020;16(1):36–42 DOI: DOI: https://doi.org/10.17925/OHR.2020.16.1.36

In 2020, an estimated 147,950 patients will be diagnosed with colorectal cancer (CRC) in the USA, with 53,200 deaths expected.1 While many patients with CRC are cured, metastatic CRC (mCRC) is still a prevalent disease, and systemic therapy options have markedly improved outcomes in patients with unresectable metastatic disease in the last several decades. Cytotoxic […]

Glimmers of Hope—New Strategies for Overcoming Treatment Resistance in Patients with BRAF V600E-mutated Metastatic Colorectal Cancer

Oncology & Hematology Review (US). 2020;16(1):31-5 DOI: https://doi.org/10.17925/OHR.2020.16.1.31

Colorectal cancer (CRC) is a commonly diagnosed malignancy and the second-leading cause of cancer death in the USA, with 147,950 estimated new cases and 53,200 estimated deaths in 2020.1 Despite CRC screening, approximately 20% of patients are diagnosed with metastatic CRC (mCRC), which carries a 14.2% 5-year survival rate.2 Over the last two decades, mCRC […]

The Evolving Role of Radiotherapy in Locally Advanced Rectal Cancer and the Potential for Nonoperative Management

Oncology & Hematology Review (US). 2020;16(1):43-51 DOI: https://doi.org/10.17925/OHR.2020.16.1.43

Colorectal cancer is the third most common cancer worldwide and the fourth most common cause of death, with 1.8 million new cases and 881,000 deaths in 2018.1 Rectal cancers account for 28% of these cancers.2 Most colorectal cancers arise from adenomatous polyps and progress to adenocarcinoma through the three major genetic pathways of chromosomal instability, microsatellite instability, […]

Circulating Tumor DNA in Colorectal Cancer—From Concept to Clinic

Oncology & Hematology Review. 2019;15(1):33–8 DOI: https://doi.org/10.17925/OHR.2019.15.1.33

Colorectal cancer (CRC) is the third most common cancer worldwide and the second most common cause of cancer-related death,1 with its incidence predicted to continue to rise significantly in the future.2 With the evolution of personalized medicine, genomic profiling is crucial for treatment and monitoring of individuals’ cancer. The increasing availability of novel molecular-targeted therapy […]

Marc Peeters, ESMO 2018 – Using Biomarkers to Guide Treatment in Colorectal Cancer

In this interview at ESMO 2018, Marc Peeters talks to touchONCOLOGY about colorectal cancer tumour location and biomarkers. He explains that left-sided cancers have a better prognosis and suggests some possible reasons for this. Dr Peeters also discusses how the use of biomarkers has developed in the last 10 years and how treatment and prognosis […]

Rita Laeufle, ESMO 2018 – Patient Selection for Abituzumab in Metastatic Colorectal Cancer

The Poseidon study was a phase I/II study in second-line KRAS mild-type metastatic colorectal cancer (mCRC) that did not meet its endpoint of progression-free survival, but did suggest a subgroup of patients with high alpha v beta 6 integrin expression who would benefit from abituzumab. In this interview, Dr Rita Laeufle tells us about the […]

John L Marshall, ASCO 2018 – PARP inhibitors for the personalized treatment of colorectal cancer

Editorial board member John L Marsahll from The Ruesch Center for the Cure of GI Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center in Washington, DC discusses unmet needs and major advances in the treatment of colorectal cancers, and how PARP inhibitors may play a role in treatment strategies in the near future. 1. […]